Checkpoint Therapeutics rises as FDA accepts application for skin cancer drug

Checkpoint Therapeutics

02/03/2023 13:26

** Shares of drug developer Checkpoint Therapeutics  CKPT.O 
up 1.63% at $5 premarket
    ** Says U.S. FDA accepted marketing application for
cosibelimab, an investigational antibody drug for patients with
a cutaneous squamous cell carcinoma, the second most common type
of skin cancer in U.S.
    ** FDA has set an action date of Jan. 3, 2024
    ** Agency indicated no potential filing review issues have
been identified, and that an advisory committee meeting to
discuss the application is not currently planned - CKPT
    ** The medication targets patients who are not candidates
for curative surgery or radiation therapy 
    ** Stock lost ~83% in 2022

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))